1365-2036/asset/olbannerleft.gif?v=1&s=45db8c78d1d41c404034f2eaf7587620d5727843)
1365-2036/asset/olbannerright.gif?v=1&s=45518840b7e2e59fcc9d74113b13f4474a604878)
You have free access to this content
Caffeine is protective in patients with non-alcoholic fatty liver disease
Article first published online: 7 NOV 2011
DOI: 10.1111/j.1365-2036.2011.04916.x
© 2011 Blackwell Publishing Ltd
Additional Information
How to Cite
Birerdinc, A., Stepanova, M., Pawloski, L. and Younossi, Z. M. (2012), Caffeine is protective in patients with non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics, 35: 76–82. doi: 10.1111/j.1365-2036.2011.04916.x
Publication History
- Issue published online: 9 DEC 2011
- Article first published online: 7 NOV 2011
- Publication data Submitted 23 August 2011 First decision 11 September 2011 Resubmitted 29 September 2011 Accepted 16 October 2011 EV Pub Online 7 November 2011
References
- 1. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221–31.
- 2, , . The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960–7. PubMed PMID: 12809815.Direct Link:
- 3, . Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008; 134: 1682–98.
- 4, , . Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010; 59: 1410–5.
- 5, , , et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524–30. e1.
- 6, , . Prevalence of elevated alanine aminotrasferase among US adolescents and associated factors: NHANES 1999–2004. Gastroenterology 2007; 133: 1814–20.
- 7. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004; 2: 1048–58.
- 8, , , , , . Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–9.
- 9, , , et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865–73.
- 10, . Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43(2 Suppl. 1): S99–112. Review.
- 11, , . Nonalcoholic fatty liver disease and the epidemic of obesity. Cleve Clin J Med 2004; 71: 657–64. Review.
- 12, , . Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006; 45: 600–6.
- 13, , , . Prevalence and trends in obesity among US adults, 1999–2008. JAMA 2010; 303: 235–41.
- 14, . Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 2004; 4: 686–93.
- 15, , , , , . Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010; 1: CD007340.
- 16, , , et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004; 164: 2169–75.
- 17, . Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 2005; 129: 1928–36.
- 18, , , . The Tromso Heart Study: distribution of, and determinants for, g-glutamyltransferase in a free-living population. Scand J Clin Lab Invest 1986; 46: 63–70.
- 19, , . The Tromso Study. Distribution and population determinants of g-glutamyltransferase. Am J Epidemiol 1990; 132: 318–26.
- 20, , , . Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol 1993; 9: 293–7.
- 21, . Distribution and population determinants of g-glutamyltransferase in a random sample of Sardinian inhabitants. ATS-SARDEGNA Research Group. Eur J Epidemiol 1996; 12: 71–6.
- 22, . Determinants of g-glutamyltransferase: positive interaction with alcohol and body mass index, negative association with coffee. Am J Epidemiol 1997; 146: 1019–24.
- 23, , , et al. Coffee consumption and decreased serum g-glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol 1998; 27: 438–43.
- 24, , , , . Coffee consumption and decreased serum g-glutamyltransferase: a study of middle-aged Japanese men. Eur J Epidemiol 2000; 16: 419–23.
- 25, . Coffee intake and mortality from liver cirrhosis. Ann Epidemiol 2003; 13: 419–23.
- 26, , , et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology. 2010; 51: 201–9. PubMed PMID: 20034049.
- 27, , , , , . Coffee consumption and reduced risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Cancer Causes Control 2011; 22: 503–10.
- 28, , , et al. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology 2011; 140: 1961–9.
- 29Analytic and Reporting Guidelines: The National Health and Nutrition Examination Survey (NHANES). Hyattsville, MD, USA: CDC/NCHS, 2005.
- 30, , , , , . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–9.
- 31, , . Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008; 47: 1947–54. PubMed PMID: 18454505.
- 32, . Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci 2005; 329: 111–6. PubMed PMID: 15767815.
- 33Available at: http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/DR1TOT_E.htm. Accessed July 4, 2011.
- 34, , , et al. Diagnosis of hepatic steatosis and fibrosis by transient elastography in asymptomatic healthy individuals: a prospective study of living related potential liver donors. J Gastroenterol 2007; 42: 382–8.
- 35, . Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008; 75: 721–8. Review.
- 36
- 37, . Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008; 48 (Suppl. 1): S104.
- 38. Pathology of nonalcoholic steatohepatitis. Hepatol Res 2005; 33: 68–71.
- 39, , , , . Coffee induces expression of glucuronosyltransferases by the aryl hydrocarbon receptor and Nrf2 in liver and stomach. Gastroenterology 2010; 139: 1699–710, 1710. e1–2.
- 40, , , , , . Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3-dependent pathways. J Hepatol 2008; 49: 758–67.
- 41, , , , . Effects of coffee on inflammatory cytokine gene expression in mice fed high-fat diets. J Agric Food Chem 2009; 57: 11100–5.
- 42, , , et al. Coffee and caffeine ameliorate hyperglycemia, fatty liver, and inflammatory adipocytokine expression in spontaneously diabetic KK-Ay mice. J Agric Food Chem 2010; 58: 5597–603.
- 43, , . Freeze-dried instant coffee can promote the activities of antioxidant enzymes and induce weight loss but also aggravate the plasma cholesterol profile in rats. Nutrition 2011; 27: 1202–5.
- 44, , , et al. Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins. Hepatology 2010; 52: 1652–61.
- 45, , , et al. Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease. Obes Surg 2007; 17: 1111–8.
- 46, , , et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27: 412–21.